Tags

Type your tag names separated by a space and hit enter

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Expert Rev Neurother 2011; 11(5):627-37ER

Abstract

People with multiple sclerosis may present with a wide range of disease symptoms during the evolution of the disease; among these, spasticity can have a marked impact on their well-being and quality of life. Symptom control, including spasticity, remains a key management strategy to improve the patient's well-being and functional status. However, available drug therapies for spasticity sometimes have limited benefit and they are often associated with poor tolerability. Sativex is a 1:1 mix of 9-delta-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with multiple sclerosis is accumulating steadily. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status when Sativex was added to the current treatment regimen. Adverse events such as dizziness, diarrhea, fatigue, nausea, headache and somnolence occur quite frequently with Sativex, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual 'uptitration'. In summary, initial well-controlled studies with Sativex oromucosal spray administered as an add-on to usual therapy have produced promising results and highlight encouraging avenues for future research.

Authors+Show Affiliations

Unitat de Neuroimmunologia Clinica, CEM-Cat, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain. jsastre-garriga@cem-cat.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21456949

Citation

Sastre-Garriga, Jaume, et al. "THC and CBD Oromucosal Spray (Sativex®) in the Management of Spasticity Associated With Multiple Sclerosis." Expert Review of Neurotherapeutics, vol. 11, no. 5, 2011, pp. 627-37.
Sastre-Garriga J, Vila C, Clissold S, et al. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother. 2011;11(5):627-37.
Sastre-Garriga, J., Vila, C., Clissold, S., & Montalban, X. (2011). THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Review of Neurotherapeutics, 11(5), pp. 627-37. doi:10.1586/ern.11.47.
Sastre-Garriga J, et al. THC and CBD Oromucosal Spray (Sativex®) in the Management of Spasticity Associated With Multiple Sclerosis. Expert Rev Neurother. 2011;11(5):627-37. PubMed PMID: 21456949.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. AU - Sastre-Garriga,Jaume, AU - Vila,Carlos, AU - Clissold,Stephen, AU - Montalban,Xavier, Y1 - 2011/04/01/ PY - 2011/4/5/entrez PY - 2011/4/5/pubmed PY - 2011/10/6/medline SP - 627 EP - 37 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 11 IS - 5 N2 - People with multiple sclerosis may present with a wide range of disease symptoms during the evolution of the disease; among these, spasticity can have a marked impact on their well-being and quality of life. Symptom control, including spasticity, remains a key management strategy to improve the patient's well-being and functional status. However, available drug therapies for spasticity sometimes have limited benefit and they are often associated with poor tolerability. Sativex is a 1:1 mix of 9-delta-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with multiple sclerosis is accumulating steadily. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status when Sativex was added to the current treatment regimen. Adverse events such as dizziness, diarrhea, fatigue, nausea, headache and somnolence occur quite frequently with Sativex, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual 'uptitration'. In summary, initial well-controlled studies with Sativex oromucosal spray administered as an add-on to usual therapy have produced promising results and highlight encouraging avenues for future research. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/21456949/abstract/THC_and_CBD_oromucosal_s L2 - http://www.tandfonline.com/doi/full/10.1586/ern.11.47 DB - PRIME DP - Unbound Medicine ER -